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Abstract: Globally, adverse drug reactions (ADRs), one of the leading causes of morbidity 
and mortality, will continue to pose a threat to public health as long as drugs are being used to 
treat various ailments. Prompt ADR reporting is crucial in ensuring drug safety. The aim of this 
narrative review was to highlight the role of pharmacists in pharmacovigilance and to identify 
barriers and facilitators toward ADR reporting documented in the literature. The perspective of 
pharmacy students on pharmacovigilance and ADR reporting has also been discussed with an 
aim to highlight the need to improve content related to ADR reporting and pharmacovigilance 
in undergraduate pharmacy curriculum. Globally, although the role of pharmacists within 
national pharmacovigilance systems varies, it is very well recognized. In general, pharmacists 
acknowledge that ADR reporting is part of their professional responsibility and have a positive 
attitude toward reporting ADRs. However, current research evidence suggests that there are still 
critical knowledge gaps with regard to ADR reporting among pharmacists, especially in coun-
tries where the role of pharmacists within the health care system is limited. These knowledge 
gaps can be fulfilled through continuous professional development programs and reinforcing 
theoretical and practical knowledge in undergraduate pharmacy curriculums. Without adequately 
identifying and fulfilling training needs of pharmacists and other health care professionals, the 
efficiency of national pharmacovigilance systems is unlikely to improve which may compromise 
patient’s safety.
Keywords: pharmacist, adverse drug reaction, pharmacovigilance, patient safety
Introduction
The World Health Organization (WHO) has defined adverse drug reactions (ADRs) 
as “a response to a drug which is noxious and unintended, and which occurs at doses 
normally used in man for the prophylaxis, diagnosis or therapy of disease, or for 
modifications of physiological function”.1 Globally, ADRs, one of the leading causes of 
morbidity and mortality, will continue to pose threat to public health as long as drugs 
are being used to treat various ailments. A recent review estimated that ADRs were 
responsible for 3.5% of the hospital admissions.2 Furthermore, ~1 in 10 hospitalized 
patients experienced an ADR in Europe.2 ADRs are the fourth to sixth leading cause 
of death in the USA,3 and it has been estimated that ADRs caused ~197,000 deaths 
annually in Europe.4 In terms of burden on health care system, a prospective UK-based 
study estimated at any one time the equivalent of up to seven 800-bed hospitals may 
be occupied by patients admitted with ADRs.5 The economic costs associated with 
ADRs are significant; in the USA, the cost per ADR in intensive care unit (ICU) and 
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non-ICU wards has been estimated at USD 19,685 and USD 
13,994, respectively.6
Pharmacovigilance (PV) is defined by WHO as “the 
science and activities related to the detection, assessment, 
understanding and prevention of adverse drug effects or any 
other possible drug-related problems.”7 The scope of PV to 
improve patients’ safety includes detection and reporting of 
ADR events, medication errors, counterfeit and substandard 
medicines, lack of efficacy of medicines, misuse and/or 
abuse of medicines, and drug–drug interactions. However, 
ADRs remain the prime focus of PV activities. Accordingly, 
this review focused primarily on pharmacists’ perspective 
pertaining to spontaneous ADR reporting.
Spontaneous reporting system (SRS) is the most widely 
used system globally to report adverse reactions by health 
care professionals, drug companies, or patients themselves 
to the national authorities regulating PV activities in the 
country.8 SRS could improve the safety profile of a particular 
drug by detecting and reporting ADRs that may not have been 
detected during premarketing clinical trials or even during 
postmarketing surveillance.9,10 Therefore, it could serve as 
a method of detection for new, rare, or serious ADR events. 
One of the main advantages of SRS is that it applies to all 
drugs during its lifetime and not limited to a period of study.11
SRS of ADR also has its limitations. Reports of low qual-
ity, known reactions, and inability to establish causal relation-
ship are frequently associated with SRS.12 In addition, SRS 
limits the potential of calculating the rates due to incomplete 
numerator data and undependable denominator.13 Moreover, 
SRS has been associated with underreporting which could 
affect new drugs and serious reactions.10 Despite its limita-
tions, SRS is considered as the most cost-effective method 
in monitoring drug safety.10
Given the voluntary nature of SRS, health care profes-
sionals, including doctors, dentists, nurses, and pharmacists, 
have an important role in ensuring that ADRs are well docu-
mented and reported. Health care professionals’ knowledge 
about and access to local ADR reporting systems, clinical 
skills in detecting an ADR, and attitude toward reporting 
ADRs are the key determinants of ADR reporting. Pharma-
cists being the drug experts have the central role in ensuring 
drug safety by detecting and reporting of ADRs. The aim of 
this narrative review was to highlight the role of pharmacists 
in SRS and to identify barriers and facilitators toward ADR 
reporting documented in the literature. The perspective of 
pharmacy students on PV and ADR reporting has also been 
discussed with an aim to highlight the need to improve 
content related to ADR reporting and PV in undergraduate 
pharmacy curriculum.
Role of pharmacists in 
ADR reporting
The role of pharmacists in ADR reporting has evolved over 
the past decade but still vary geographically.14–16 Over a 
decade ago, in Scandinavian countries, pharmacists were 
not allowed to report ADRs independently.17 In the UK, 
pharmacists were only allowed to independently report ADRs 
after 10-year long debate and struggle.18 Contrastingly, in 
Malaysia, in 2010, pharmacists contributed more than half 
of the total ADR reports received by the Malaysian National 
Pharmacovigilance Center.15 An international survey of 41 
member states participating in the WHO Drug Monitoring 
program published in 2004 also found considerable variations 
in the role of pharmacists in reporting ADRs.14 The variation 
in the role of pharmacists in PV activities can be explained by 
the variations in pharmacists’ role within health care system 
across the globe from mere “dispenser” to the guardian of 
drug safety and patient outcomes. As the role of pharmacists 
within the health care systems continues to evolve, their role 
in ADR reporting is getting recognized. Research evidence 
shows that recruitment of pharmacists in public hospitals 
can not only detect and report ADRs but also prevent ADRs 
and reduce associated humanistic and financial costs.18,19 
Furthermore, hospital pharmacists are more likely to report 
ADRs compared with community pharmacists.14 This could 
be explained by the fact that pharmacists with a clinical back-
ground have greater awareness about ADR reporting system 
and are frequently engaged with prescribers.20 Furthermore, 
regular contact with the patients coupled with the access to 
patients’ medical records allows clinical pharmacists at the 
hospitals to develop a better understanding of the suspected 
ADRs.21 Nevertheless, being the most accessible health care 
professional, community pharmacists have a crucial role in 
ensuring drug safety as well by detecting and reporting ADRs, 
especially in areas where access to general practitioners/
primary care physicians is limited.
Pharmacists’ perspective on 
ADR reporting
Given that both community and hospital pharmacists can play 
an important role in ADR reporting, a number of studies have 
been conducted globally to evaluate knowledge, attitudes, and 
practices of pharmacists toward ADR reporting with an aim to 
identify knowledge, attitudes, practices, and barriers to ADR 
reporting, so that appropriate interventions can be designed 
and implemented to overcome these barriers.21–36 A summary 
of studies evaluating pharmacists’ knowledge and practices 
toward ADR reporting published between 2011 and 2016 
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are presented in Table 1. In general, pharmacists expressed 
willingness to report ADRs and considered ADR reporting as 
part of their professional responsibility. However, a number 
of barriers to ADR reporting experienced by pharmacists 
have also been identified in the literature.21–38 Broadly, these 
barriers can be classified as health system-related barriers and 
individual pharmacist-related barriers (Figure 1). Although a 
number of these barriers are interrelated, this broad classifica-
tion is made just for ease of comprehension and to identify 
potential target areas for interventions aimed at improving 
ADR reporting rates.
The most commonly reported barrier is the lack of 
knowledge about local reporting guidelines and policies and 
establishing ADR causation with suspected drug. Another 
well-documented misconception among pharmacists is to 
report only serious and/or new ADRs. In the UK, a study 
evaluating the knowledge and attitudes of hospital phar-
macists toward ADR reporting reported that almost half 
of the participants were unclear about what type of ADRs 
should be reported.37 Similarly, another study conducted 
in People’s Republic of China aimed to identify reasons 
for underreporting of ADRs by hospital pharmacists and 
concluded that the inability of hospital pharmacists to 
establish the seriousness of an ADR was one of the barriers 
to ADR reporting.29 The uncertainty of pharmacists toward 
ADR reporting could have been influenced by their lack of 
awareness about ADR reporting. Furthermore, pharmacists 
may be reluctant to report minor reactions and would only 
report an ADR once they have established the association 
of the ADR with the suspected drug.38 Concern of submit-
ting inappropriate reports is also a commonly cited barrier 
to ADR reporting.38
From the discussion above, it is evident that pharmacists’ 
knowledge and attitudes have influence on ADR report-
ing. Subsequently, in almost all the cross-sectional studies 
conducted across the globe, pharmacists themselves have 
highlighted the need for more training both in detecting and 
reporting ADRs. Therefore, many of the studies concluded 
that continuous training, providing feedback to reporters 
and providing incentives (either financially or in term of 
continuous pharmacy education points) could be the  effective 
methods in persuading more active involvement from com-
munity pharmacists in PV activities.
Strategies to improve ADR 
reporting
As a broad principle, strategies for improving ADR report-
ing should be targeted both at the health care system level 
and individual pharmacist level. In addition to encouraging 
 pharmacists to report ADRs, their knowledge and skill defi-
cits in detecting and reporting ADRs should also be fulfilled 
through continuous professional development programs. 
Evidence suggests that provision of continuous education 
to health professionals is instrumental in changing their 
behaviors and attitudes toward ADR reporting.39,40 The aim 
of such education should not only be limited to improve the 
pharmacists’ knowledge about ADRs but also be directed to 
change their attitudes and perceptions toward ADR report-
ing. Studies have also reported that increased training is 
associated with an increased likelihood to ADR reporting.37,41 
Nonmonetary incentives (e.g., certificate of recognition) for 
pharmacists who report ADRs is another method of improv-
ing spontaneous reporting of ADRs.36,40,41
On health-system level, to engage community pharma-
cists more in ADR reporting, providing community phar-
macists with access to patient’s medical and medication 
history will enable pharmacists to establish ADR causation 
and report ADRs as inability to establish causation deter 
pharmacists from reporting ADRs. Research evidence also 
suggests that electronic ADR tools can also improve spon-
taneous reporting of ADRs.42,43 Introduction and integration 
of electronic ADR reporting system with hospital informa-
tion system at a 400-bed tertiary hospital in Spain led to an 
increase in the ADR reports submitted to the PV center.43 
The integrated ADR tool also allowed easier analysis of 
submitted ADR reports and automatic  notification of sus-
pected allergies to the allergy  department.43 The effective-
ness of electronic reporting in improving the spontaneous 
reporting of ADRs has been reported at a children hospital 
in the UK as well.42 This study was conducted to assess the 
impact of electronic reporting and monitoring of ADRs in 
children and to determine whether it could supplement the 
conventional Medicines and Healthcare Products Regula-
tory Agency Yellow card reporting system (standard ADR 
reporting form used in the UK). During the study period, 87 
ADR reports were submitted through the electronic system 
compared with only 8 ADR reports, which were submit-
ted to the Yellow card scheme suggesting the superiority 
of electronic reporting system compared with traditional 
paper-based reporting system.42
Perspective of undergraduate 
pharmacy students
It is imperative to ensure that pharmacy students, the future 
pharmacists, are well trained and have sufficient knowledge 
pertaining to procedures and importance of ADR reporting.44 
They should be able to recognize, prevent, and repot an ADR. 
There are nine studies exploring the pharmacy students’ 
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Table 1 Summary of studies evaluating knowledge, attitude, and practices of pharmacists toward ADR reporting
Study ID Methods Results
Method/population Sample size Instrument Knowledge Attitude/practices
Suyagh 
et al35/
Jordan
Cross-sectional/
community and 
hospital pharmacists
208 (130 
community 
pharmacists; 
78 hospital 
pharmacists)
Questionnaire Only 19.2% and 
67.7% could define PV 
and ADR correctly, 
respectively. 68.5% 
were not aware of 
the existence of PV 
center in Jordan and 
85.4% did not know 
about the official ADR 
reporting form.
Reasons for not reporting: lack of 
information from patient; ADR form not 
available; unaware of existence of national 
PV system; ADR too trivial.
Mahmoud 
et al30/Saudi 
Arabia
Cross-sectional/
community 
pharmacists
147 Questionnaire Only 22.1% were 
familiar with ADR 
reporting process in 
Saudi Arabia and 80% 
were not aware of the 
availability of online 
reporting system.
87.5% did not report ADR if they 
encountered one and referred patients 
to physicians. Unaware of reporting 
method, ADR reporting being physicians’ 
responsibility, and ADRs encountered 
by community pharmacists are usually 
minor and need not to be reported were 
the most common reasons cited for not 
reporting ADRs.
Khan28/Saudi 
Arabia
Cross-sectional/
community 
pharmacists 
50 Questionnaire 92% could define ADR 
and 90% were not 
aware of the existing 
ADR reporting system 
available in Saudi.
Major reasons for not reporting included: 
unavailability of professional ambience to 
discuss ADR; ADR form not available; 
reporting form is complicated; it is time 
consuming.
Elkalmi 
et al25/
Malaysia
Cross-sectional/
community 
pharmacists 
116 Questionnaire Only 11.6% could 
define PV correctly 
and 75% were not 
aware the existence 
of PV system. 68.3% 
did not know that 
ADR reports can be 
submitted online.
Reasons for not reporting ADRs included: 
did not know how and where to report; 
ADR form not available; serious ADR 
already detected prior registration.
Al-hazmi 
and 
Naylor23/
Saudi Arabia
Cross-sectional/
community 
pharmacists 
170 Face to face 
interviews
Only 18% were aware 
of the national ADR 
reporting system and 
more than half (56%) 
of the respondents 
did not know about 
the existence of the 
national PV center.
38.8% agreed that pharmacists are 
responsible for reporting ADRs. 94.1% 
felt that ADR reporting should be made 
compulsory. ADR form not available, did 
not care to report, ADR already known, 
and did not know how to report were the 
common reasons for not reporting ADRs.
Qassim 
et al33/UAE
Cross-sectional/
community 
pharmacists
223 Questionnaire Only 4.9% of the 
participants had good 
knowledge score. 
44% were not aware 
about ADRs reporting 
program in UAE.
93.7% had a positive attitude toward 
reporting ADRs. However, only 3.6% of 
the participants had sent ADR reports to 
MOH or the pharmaceutical companies at 
least once.
Jose et al27/
Oman
93.7% had a 
positive attitude 
toward reporting 
ADRs. However, 
only 3.6% of the 
participants had 
sent ADR reports 
to MOH or the 
pharmaceutical 
companies at least 
once.
88.8% of the 
pharmacists were 
aware of the national 
PV program in Oman. 
However, 20.5% 
thought that only 
adverse reactions to a 
new drug need to be 
reported.
90.6% considered it part of their 
professional obligation of pharmacists. 
Sixty four percent rejected the notion 
that ADR reporting would increase 
unnecessary workload. 91.5% and 86.9% 
of pharmacists would inform patient 
regarding important side effects of a 
medication and regarding actions needed 
to avoid ADRs, respectively.
(Continued)
 
In
te
gr
at
ed
 P
ha
rm
ac
y 
Re
se
ar
ch
 a
nd
 P
ra
ct
ice
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
7.
18
8.
10
8.
16
8 
on
 1
5-
No
v-
20
18
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Integrated Pharmacy Research and Practice 2017:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
95
Pharmacists in pharmacovigilance
Study ID Methods Results
Method/population Sample size Instrument Knowledge Attitude/practices
Duarte 
et al24/
Portugal
Mixed-methods/
community 
pharmacists
154 Questionnaire 
and qualitative 
interviews
One-quarter of 
the respondents 
were familiar with 
the new ADR 
definition. 38.3% had 
previously reported 
an ADR. Educational 
interventions were 
believed to be the 
main facilitator.
ADR reporting was considered as very 
important by 66.9% of the respondent. 
Unsure of causal association between 
drug and reactions, lack of time, and ADR 
already known were commonly cited 
barriers.
Yu et al36/
South Korea
Cross-sectional/
community 
pharmacists
1001 Questionnaire 95.5% recognized 
pharmacists’ duty 
to report ADRs. 
However, only 77% of 
the respondents knew 
about the national PV 
system in Korea.
87.1% of the respondent had encountered 
ADR but only 29.4% had reported an 
ADR. Among reasons for not reporting 
ADRs were ADR was not serious; 
already known ADR; and unsure of causal 
relationship between drug and reactions.
Rabba and 
Mohammad32/
Saudi Arabia
Cross-sectional/
community 
pharmacists
53 Questionnaire Only 25% were aware 
of the existence of the 
PV system in Saudi 
Arabia and 74% of the 
participants did not 
know where to report 
ADR if encountered.
85% considered ADR reporting as 
pharmacists’ responsibility and 95% 
believed that PV is important. ADR form 
not available; confidentiality; and inability 
to establish causation were the commonly 
cited reasons for not reporting ADRs.
Hadi et al26/
Malaysia
Cross-sectional/
hospital pharmacists
163 Questionnaire 95.0% and 79.1% 
correctly identify 
definitions of ADRs 
and PV, respectively. 
97.5% were aware on 
how to locate an ADR 
form. 95.0% of the 
pharmacists involved 
also knew that ADR 
should be sent to 
MADRAC.
All pharmacists agreed that ADR reporting 
is part of their professional responsibility. 
Reasons for not reporting ADRs included: 
lack of information from patient; ADR 
already well known; minimal feedback 
received, and too busy to report.
Liu et al29/ 
People’s 
Republic of 
China
Case–control (case 
– pharmacists who 
had reported ADR 
between January 2008 
and December 2010; 
control – pharmacists 
who had not 
reported ADR for the 
same period)/hospital 
pharmacists
558 (186 from 
cases and 372 
from controls)
Questionnaire Pharmacists who had 
reported an ADR 
had higher compared 
to those who had 
not (p=0.005). More 
than half were of the 
availability of phone 
reporting and e-mail 
reporting.
Majority agreed that reporting ADR is the 
professional responsibility of pharmacists. 
Most of the participants agreed that easier 
reporting system can increase reporting 
rate. Top three reasons cited that might 
affect ADR reporting were seriousness 
of the reaction, expected reaction to the 
drug, and lack of mandatory regulation on 
ADR reporting.
Obara 
et al31/Japan
Cross-sectional/
community 
pharmacists
1795 Questionnaire About 77% did 
not understand 
the national ADR 
reporting system 
and pharmacists’ 
knowledge was 
significantly associated 
with gender, age, level 
of education, working 
experience, and 
number of pharmacists 
in the hospital.
Reasons for not reporting ADR were well-
known reaction, unsure of causal relation 
between drug and reactions, and did not 
know how to report and ADR.
Abbreviations: ADR, adverse drug reaction; PV, pharmacovigilance; MADRAC, Malaysian Adverse Drug Reactions Advisory Committee; MOH, Ministry of Health.
Table 1 (Continued)
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Figure 1 Barriers toward ADR reporting experienced by pharmacists.
Abbreviation: ADR, adverse drug reaction.
Barriers to ADR reporting
Health system-related
barriers
Lack of access to patient
records
Fear of litigation
Lack of clear reporting
guidelines
Lack of financial
rewards/incentives
Individual pharmacist-related
barriers
Knowledge and clinical
competence
Inability to establish
causality
Lack of understanding the responsibility
of reporting ADRs
How/where to report
Attitudes toward reporting
ADRs
Self-guilt of harming
patients
Lack of interest
Lack of time
perspectives in PV and ADR reporting. Therefore, a number 
of studies have evaluated perspective of pharmacy students 
toward PV and ADR reporting.44–51 All were cross-sectional 
studies, using a structured validated questionnaire, involved 
mainly the Bachelor of Pharmacy (BPharm) students.44–51 Only 
one study44 was conducted in the Western country (i.e., the 
USA), whereas the rest were carried out in Asian region.44–51
The majority of the published studies investigated knowl-
edge, attitudes, and perception of the pharmacy students 
on ADR reporting,44–51 except one that also looked into the 
practice aspect of PV and ADR reporting.47 In general, most 
studies reported that the pharmacy students had insufficient 
knowledge in PV or ADR reporting.34,44,45,47,48 Approximately 
only 24.4%–62.4% of the pharmacy students were able to 
define PV and ADR correctly44,48,49,51 and less than half of 
them knew the exact mechanism of ADR reporting (e.g., 
where to obtain ADR reporting form, when to report, and 
whom to report).45,47,48 In certain studies, up to 88% of the 
surveyed students did not know how causality assessment 
of an ADR is being conducted,49 and 70%–80% of them did 
not know about the PV program in the nation,48,51 reflecting 
their poor knowledge in this area.
Of note, Doctor of Pharmacy (PharmD) students were 
significantly more knowledgeable in PV and ADR reporting 
when compared with BPharm students.46,47 Likewise, in the 
study by Saygi et al,34 higher knowledge score in PV was 
reported among the fifth year BPharm students than those in 
the first year of the pharmacy study. The level of knowledge 
regarding PV among the pharmacy students was found to be 
significantly associated with their previous exposure to the 
relevant topics, such as PV, ADR reporting, and pharmacoepi-
demiology.45,46 Also, it was noted that pharmacy students who 
had any previous experience or exposure to ADR would have 
significantly better knowledge in PV and ADR reporting.45,46
Pharmacy students generally expressed a positive atti-
tude toward PV and ADR reporting.44,46–48,50 The majority of 
the surveyed pharmacy students agreed that PV is crucial, 
and all health care professionals including pharmacists 
should actively report ADR in their daily practices.46–48,50 
Most believed that by reporting ADR can educate others 
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about the risk of the drugs, improve patient safety, and it is 
personally rewarding.44 No significant difference in attitude 
was observed between the PharmD and BPharm students,46 
except more PharmD students considered ADR reporting as 
their major responsibilities being a pharmacist.
The perception and barriers toward PV and ADR report-
ing among the pharmacy students have been explored; most 
BPharm students have indicated that limited training and 
exposure to PV and ADR reporting were the major reasons 
for their poor knowledge and lack of preparedness in han-
dling ADR reporting cases.44–48,50,51 About 30%–50% of the 
BPharm students reported that they had taken a PV course 
or felt that the PV-related topics had been well covered in 
the curriculum.44,45,49 However, PharmD students claimed 
that they were adequately trained to handle ADR reporting.46 
Accordingly, more emphasis in PV topics should be given 
in the BPharm courses to sufficiently prepare them for ADR 
monitoring and reporting when working as pharmacists in 
the future. In addition, the majority of the pharmacy students 
(i.e., 81.9%–86%) perceived that the paucity of information 
provided by the patients was one of the major barriers toward 
ADR reporting.46 Indeed, this insufficient information had led 
to the difficulty in causality assessment of an ADR. The lack 
of encouragement and incentives by the relevant authorities 
in ADR reporting was another main reason of underreporting 
among the pharmacy students.44,46 The pharmacy students 
agreed that the use of health information technologies (e.g., 
online reporting system), the provision of legal protection by 
the relevant authorities, and the mandatory in ADR reporting 
would ensure a proper and effective PV process.46
Conclusion
Pharmacists, being drug experts and guardian of safe and 
effective use of medicines, have an important role in not 
only detecting, reporting, and monitoring of ADRs but also 
preventing ADRs. Knowledge gaps with regard to ADR 
reporting still exist among pharmacists, especially in coun-
tries where the role of pharmacists is still in transition from 
being product oriented to patient oriented. These knowledge 
gaps can be fulfilled through continuous professional devel-
opment programs and reinforcing theoretical and practical 
knowledge in undergraduate pharmacy curriculum. Engag-
ing community pharmacists in ADR reporting by giving 
them access to patient’s medical record and introducing 
electronic reporting system can also improve ADR reporting 
rate. Without adequately identifying and fulfilling training 
needs of pharmacists and other health care professionals, the 
efficiency of national PV systems are unlikely to improve, 
which may compromise patient safety.
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